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Immunohistochemical expression of the c-kit proto-oncogene product in
human malignant and non-malignant breast tissues
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Summary The immunohistochemical expression of c-kit proto-oncogene product in 57 breast cancer tissues
was studied using anti-c-kit proto-oncogene product antibody in comparison with 20 normal breast tissues and
58 benign breast tumours. In normal breast tissues, the c-kit proto-oncogene product was strongly expressed on
cell membrane and/or cytoplasm of alveolar and ductal cells. The immunoreactive score (IRS) of c-kit proto-
oncogene product in normal mammary epithelia was 6.22+2.11 (mean+s.d.). In benign breast diseases, the c-
kit proto-oncogene product was detected heterogeneously with a reduced IRS (3.33+2.44). In breast cancer
tissues, the expression of the immunoreactive c-kit proto-oncogene product was often deleted and the average
IRS was significantly reduced compared to those of normal breast tissues or benign breast disease tissues.
Among benign diseases, the average IRS of intraductal papilloma was significantly reduced (1.34+1.70) and
the staining intensity and pattern were found to be similar to those seen in breast cancer. The results in this
study suggested that the c-kit proto-oncogene product is correlated with the growth control or the
differentiation of normal breast epithelium. Also, the loss of the expression of this protein may indicate the
change of the signal transduction in relation to malignant transformation in human mammary epithelium.
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The c-kit proto-oncogene encodes a transmembrane tyrosine
kinase receptor with a molecular weight of 145 000 Da,
which is structurally similar to the platelet-derived growth
factor receptor and the colony-stimulating factor-I receptor
(Qiu et al., 1988). Recent studies have demonstrated that the
c-kit proto-oncogene product is expressed in a restricted
number of human fetal, adult tissues and solid tumours
(Natali et al., 1992a; Matsuda et al., 1993).
Analysis of the tissue expression of the c-kit proto-
oncogene in the breast tissues has shown that normal
epithelium contained large amounts of c-kit-specific RNA
transcripts (Natali et al., 1992b). Immunohistochemically,
homogenous expression of c-kit proto-oncogene product in
normal mammary epithelia, and the loss of expression of this
protein in breast cancer has been demonstrated using fresh
frozen sections (Natali et al., 1992b). However, little is known
about the biological significance of this protein in benign and
malignant diseases of the breast. To elucidate the relationship
between the loss of this protein and the malignant
transformation of human breast tissue, the immunohisto-
chemical expression of the c-kit proto-oncogene product in
malignant and non-malignant breast tissues was examined
using paraffin-embedded sections on a comparative basis.
Materials and methods
Tissues
Fifty-seven patients with primary breast cancer and 58
patients with benign breast disease were studied. All patients
were female and the ages of patients with breast cancer and
benign disease ranged from 29 to 73 years (average age 51.8
years) and from 22-89 years (average age 43.7 years)
respectively. Furthermore, normal breast tissues were
obtained from 20 surgical specimens of mastectomised
patients. Tissues were fixed in 10% buffered formalin and
embedded in paraffin. One serial section from each tissue
sample was stained with haematoxylin and eosin for routine
histological examination and others were treated for
demonstration of the c-kit proto-oncogene product, as
described below.
Histopathological classification
The benign breast disease and the breast cancer were
diagnosed according to the General Rules for Clinical and
Pathological Recording of Breast Cancer (Japanese Breast
Cancer Society, 1992). The breast cancer was classified into
three types: four cases of non-invasive carcinoma, 50 cases of
invasive ductal carcinoma and three of mucinous carcinoma.
Four cases of non-invasive carcinoma were all non-invasive
ductal carcinoma, and 50 cases of invasive ductal carcinoma
consisted of 29 solid tubular, 10 papillotubular and 11
scihrrous carcinoma. Benign disease was classified into three
types: 23 cases of fibrocystic change, 20 of fibroadenoma and
15 of intraductal papilloma.
Antibody
Commercially available anti-c-kit rabbit IgG (K963; IBL,
Fujioka, Japan) was used. It was derived by immunising
rabbit with the carbon-terminal peptide of c-kit (tyrosine
kinase receptor) as immunogen (Matsuda et al., 1993).
Immunohistochemistry
ABC kits (Vector Laboratories, CA, USA) for rabbit IgG
were used. Four micron tissue sections were deparaffinised
with xylene and rehydrated with a series of ethanol solutions.
Tissue sections were incubated in normal goat serum for
30 min, incubated overnight at 4°C with optimally diluted
primary antibody and subsequently incubated with biotiny-
lated anti-rabbit IgG and avidin-biotin alkaline phosphatase
complex (AK-5100; Vector Laboratories, CA, USA) for
60 min at room temperature. They were washed in 0.01 M
phosphate-buffered saline (PBS, pH 7.2) between each
incubation step. Then, the alkaline phosphatase substrate I
(SK-5100; Vector Laboratories, CA, USA) in the presence of
1.25 mmol 1` levamisole (SP-5000; Vector Laboratories, CA,
USA) was used for signal detection. All sections were
counterstained with Mayer's haematoxylin. SCLC was used
as a positive control for c-kit proto-oncogene product
staining in which c-kit proto-oncogene product is known to
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be detectable (Natali et al., 1992a). For the negative controls,
the following procedures were employed: (1) sections were
processed without the primary antibody, and (2) rabbit IgG
(Zymed Laboratories, CA, USA) was used instead of the
primary antibody.
Evaluation for immunohistochemical reactivity
Evaluation of the cell staining reaction was performed in
accordance with the following immunoreactive score (IRS)
proposed by Remmele and Stegner (1986) with slight
modification as follows: IRS=SI (staining intensity) x PP
(percentage of positive cells). SI was determined as 0,
negative; 1, weak; 2, moderate; and 3, strong. PP was
defined as 0, negative; 1, 1-20% positive cells; 2, 21-50%
positive cells; 3, 51-100% positive cells. Ten visual fields
from different areas of each specimen were chosen at random
for the IRS evaluation and the average IRS was calculated as
final value.
Statistical analysis
The data obtained were evaluated as follows: difference
between the means of continuous variables was calculated
using unpaired Student's t-test. Follow-up survival analysis
was performed by the Kaplan-Meier method and compar-
ison between individual subgroups was performed using the
generalised Wilcoxon test. The probability level of <0.05 was
taken as the limit of significant difference.
Results
Normal breast tissue
The expression of c-kit proto-oncogene product was observed
homogeneously in the cytoplasm and/or on cell membrane of
alveolar and ductal mammary epithelia in all specimens
(Figure la). The average IRS of normal breast tissue was
6.22+2.11 (mean+s.d.) (Table I).
Benign breast tissue
In benign breast tissue, the expression was found to be
distributed heterogeneously in the cytoplasm or on the cell
membrane of tumour cells (Figure lb-d). The average IRS
of c-kit proto-oncogene product expression tended to be
reduced as 3.33+2.44 in 58 benign breast diseases (Table I).
Especially in intraductal papilloma of the breast, the IRS was
significantly reduced to 1.34+1.70, compared with that of
fibrocystic change (IRS, 3.88+2.45) or of fibroadenoma
(IRS, 4.11 +2.16) (Table II).
Breast cancer
In breast cancer, the expression of c-kit proto-oncogene
product was often deleted. Even in the tumour showing
positive staining, the expression was observed in the
cytoplasm and/or on the cell membrane of the limited
number of cancer cells (Figure 2). The expression was found
Table I Expression of c-kit proto-oncogene product in normal
epithelia and in breast tissue from patients with benign diseases and
malignant tumours of the breast
Source Number IRS ofc-kit expression
oftissue of tissues (mean±s.d.)
Normal epithelium 20 6.22 ±2.11*
Benign breast tissue 58 3.33 ±2.44*
Breast cancer tissue 57 0.43 ± 1.27*
*P=0.0001.
Figure 1 Immunohistochemical expression ofc-kit proto-oncogene product in human normal breast tissues and benign diseases. (a)
Normal mammary epithelia. Bar =25tm. All of the epithelial cells expressed c-kit proto-oncogene product on plasma membrane or
in the cytoplasm. (b) Fibrocystic change. The expression of c-kit proto-oncogene product was observed in the ductal epithelial
hyperplasia in the lesion of fibrocystic change. Bar =25 um. (c) Intraductal papilloma. Bar = 50pm. (d) Fibroadenoma. Bar=50pm.
b-d represent the heterogeneous expression of c-kit proto-oncogene product in benign breast diseases.
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to be restricted in cancer cells showing acinar differentiation
(Figure 2c). The average IRS of breast cancer was only
0.43 + 1.27 (Table I). The complete deletion was found in 40
Table II Expression of c-kit proto-oncogene product in benign
diseases of the breast
Benign Number IRS ofc-kit expression
diseases of tissues (mean±s.d.)
Fibrocystic change 23 3.88 + 2.45*
Fibroadenoma 20 4.11 +2.16**
Intraductal
papilloma 15 1.34+ 1.70*
*P=0.0013; **P=0.0003.
of 57 (70.2%) breast cancer tissues. The IRS of c-kit proto-
oncogene product expression in primary breast cancer was
significantly lower compared to those of the normal breast
tissues ofthe benign breast diseases (P=0.0001) (Table I). To
evaluate the changes of c-kit proto-oncogene product
expression during malignant transformation in the human
breast, the relationship between the IRS of normal duct,
intraductal papilloma, non-invasive and invasive carcinoma
was studied (Table III). The IRS of intraductal papilloma
was significantly lower than that of normal duct. Although
Table III Changes in the expression of c-kit proto-oncogene
product in human breast diseases
IRS of c-kit
Number expression
Tissues of tissues (mean±s.d.)
Normal duct 16 7.13±1.82
Intraductal
papilloma 15 1.34+ 1.70:
Non-invasive
carcinoma 4 0.90± 1.55-
Invasive
carcinoma 50 0.41 ±.129
* P=0.0001; tP
=0.0277.
*
Figure 2 Immunohistochemical expression of c-kit proto-
oncogene product in human breast cancer. (a) The staining of
immunoreactive c-kit proto-oncogene protein was distributed
focally in this breast cancer tissue. (b) Complete deletion of the
expression of c-kit proto-oncogene product was observed in
cancer cells. In contrast, diffuse staining was observed on the
alveolar mammary epithelia in this specimen. (c) The expression
of c-kit proto-oncogene product was detected on cancer cells
showing acinar differentiation. Bar=50,um.
Table IV Correlation between the expression of the c-kit proto-
oncogene protein and the clinicopathological parameters of breast
cancer
IRS of c-kit
Number of expression
Parameters tissues (mean ±s.d.) P-value
ER
(-) 31 0.51+ 1.67
(+) 26 0.36±0.84 NS
Menopausal status
pre- 26 0.44±0.92
post- 31 0.42+ 1.52 NS
Tumour size
TI 20 0.55+ 1.87
T2 25 0.40±0.91
T3 8 0.43 i0.69 NS
T4 4 0.00±0.00
Histological
Solid tubular 29 0.46± 1.58
Papillotubular 10 0.50+ 1.01
Scirrhous 11 0.22± 0.48 NS
Non-invasive 4 0.90+ 1.55
Mucinous 3 0.00+ 0.00
Differentiation
I 19 0.41 ±0.38
II 23 0.69+0.18 NS
III 15 0.38± 0.84
Lymph node
metastasis 27 0.56± 1.70
NO 15 0.75+ 1.69
Nla 8 0.09+0.25 NS
Ni,B 1 0.00+0.00
N2 3 0.67+ 1.16
N3
Distant
metastasis
MO 41 0.43+ 1.40
M 16 0.41+0.91 NS
TNM stage
I 29 0.53+1.64
II 11 0.21+ 0.47
III 1 0.00+ 0.00 NS
IV 16 0.41+0.91
IRS, immunoreactive score; ER, oestrogen receptor; NS, not
significant.
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no significant difference was found between non-invasive and
invasive carcinoma, the IRS of intraductal papilloma was
higher than that of invasive carcinoma, and the intensity and
the pattern of the staining were found to be similar to those
seen in non-invasive carcinoma.
No significant relationship was found between the expres-
sion ofthe c-kit proto-oncogene product and the clinicopatho-
logical parameters of the breast cancer, such as grade of
differentiation, tumour size, lymph node metastasis, distant
metastasis, TNM stage, presence ofER, andmenopausal status
of the patient (Table IV). The patients were followed-up for
three years in this study and no significant association was
observed between the expression of this protein and the
prognosis ofpatients with breast cancer.
Discussion
The immunoreactive expression of c-kit proto-oncogene
product was not observed in human normal lung or seminal
vesicles tissue (Natali et al., 1992a; Matsuda et al., 1993),
whereas itwas found in 56% ofSCLC (Matsuda etal., 1993 and
80% ofseminomas (Strohmeyeretal., 1991). Ontheotherhand,
the expression was diffusely observed in human melanocytes,
but, in primary melanomas, the deletion of the c-kit proto-
oncogeneproductwas observed inmoreinvasivelesions (Natali
et al., 1992c). Previously a complete inverse pattern of the
expression ofc-kitproto-oncogene product has also been found
in the normal tissues and the malignant tumours of the breast
(Natali et al., 1992a; Matsuda et al., 1993).
In the present study the c-kit proto-oncogene product was
uniformly expressed in normal breast tisses. In contrast, it
was expressed heterogeneously in benign breast disease and
the deletion was observed in breast cancer specimens with
high incidence suggesting that the reduced c-kit proto-
oncogene product expression is a general phenomenon in
breast cancer. Previous studies have shown that direct cell-
cell interaction between c-kit and its ligand, the membrane-
bound form of stem cell factor (SCF), plays an important
role in signal transduction (Flanagan, et al., 1991; Reith et
al., 1991). Therefore, the high expression of the c-kit proto-
oncogene product in normal breast tissue indicated that this
protein may be related to the regulation of the proliferation
and/or the differentiation of human normal mammary
epithelia through the c-kit signalling pathway. Although it
is possible to consider that the absence of staining in
neoplastic cells is due to the presence of mutant c-kit
product which is not reactive with the antibody used, the
deletion of c-kit proto-oncogene product in breast cancer
may indicate the changes of the signal transduction during
malignancy in human mammary epithelia.
Recently, clonal analysis by means of polymerase chain
reaction revealed that the intraductal papilloma was
monoclonal in origin consisting of breast carcinoma,
indicating that certain genetic changes had already occurred
in the intraductal papilloma (Noguchi et al., 1992, 1994). In
the present study we found that the IRS of c-kit proto-
oncogene product in intraductal papilloma was significantly
reduced compared with that of other benign breast diseases.
Since the loss of the expression of this protein could be
considered to be related to the malignant transformation of
human mammary epithelia (Natali et al., 1992b), the
observations in this study may indicate that the intraductal
papilloma possesses higher malignant potential in benign
breast diseases.
In this study no significant relationship was found between
the expression of c-kit proto-oncogene product and the
clinicopathological factors of breast cancer, although it is
well known that the c-kit proto-oncogene product displays
pleiotropic functions, such as the migration of the pigment
stem cells (Keshet et al., 1991) and the proliferation of the
mast cells during normal development (Wershil et al., 1992).
The reduction of c-kit proto-oncogene product expression
observed in intraductal papilloma as well as breast cancer
cells suggested that the deletion of c-kit proto-oncogene
product would occur in the early phase of malignant
transformation of human mammary epithelia. Further
investigations will be required to clarify the active mechan-
ism of c-kit proto-oncogene product in human breast.
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